Pharmafile Logo
Pharmafocus logo
Advanced Search

Cosentyx

Showing 15 posts of 34 posts found.

novartis_outside_1

Novartis reveals strong long-term data Cosentyx in psoriasis of the hands and feet

December 1, 2017
Medical Communications, Research and Development Cosentyx, Novartis, palmoplantar psoriasis, pharma, psoriasis

Novartis has released new data for Consentyx (secukinumab) which it claims make the IL-17A inhibitor “the first biologic to show …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

September 15, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cosentyx, Eli Lilly, Martin Skreli, Teva, pharma, top ten

This week has been a particularly eventful one for the industry: among our top stories, Martin Shkreli finally heads to …

News

Novartis’ Cosentyx proves long-term efficacy in psoriasis skin clearance

September 13, 2017
Research and Development Cosentyx, Novartis, pharma, pharmaceutical, psoriasis

At the European Academy of Dermatology and Venereology Congress in Geneva, Switzerland, Novartis unveiled new Phase 3 data for Cosentyx …

News

Novartis’ Cosentyx shines in ankylosing spondylitis and psoriatic arthritis

June 15, 2017
Research and Development Cosentyx, Novartis

Novartis has released new data on the efficacy of its drug Cosentyx (secukinumab) in the treatment of life-long inflammatory diseases …

News

Novartis’ psoriasis drug allows some patients to go into remission

March 21, 2017
Research and Development Cosentyx, Novartis, psoriasis

Novartis released data on patient’s reaction to Cosentyx for the treatment of psoriasis, finding that as many as 21% of …

News

Novartis reveals positive three-year efficacy data for psoriatic arthritis drug

November 15, 2016
Manufacturing and Production, Research and Development Cosentyx, Novartis, psoriatic arthritis

Novartis has claimed that its Cosentyx (secukinumab) treatment is now the first approved fully human interleukin-17A (IL-17A) inhibitor to demonstrate …

News
novartis_window

Novartis reveals impressive four year data upon Cosentyx

October 3, 2016
Sales and Marketing Cosentyx, Novartis, psoriasis

Novartis announced on October 1 that Cosentyx (secukinumab) had delivered a high percentage and long-lasting skin clearance in patients with …

News
novartis_iobmr

NICE recommends Cosentyx in ankylosing spondylitis

August 4, 2016
Research and Development, Sales and Marketing Cosentyx, NICE, Novartis, ankylosing spondylitis

Novartis has announced that the National Institute for Health and Care Excellence (NICE) has recommended Cosentyx (secukinumab) to treat adults …

News
novartis_side_building

Novartis to compare Cosentyx with Humira in new clinical trials

June 8, 2016
Research and Development Cosentyx, Humira, Novartis, comparison, eular 2016

Novartis has announced that it plans to directly compare Cosentyx (secukinumab) versus Humira (adalimumab) in patients with ankylosing spondylitis and …

News

Novartis says its psoriasis drug bests Janssen’s in comparison study

March 7, 2016
Research and Development, Sales and Marketing Cosentyx, Novartis, Stelara

Novartis has announced new data from a study comparing its drug Cosentyx to Janssen’s Stelara, which it says demonstrates Cosentyx’s …

News
cosentyx

Two new US approvals for Novartis’ Cosentyx

January 18, 2016
Research and Development, Sales and Marketing Cosentyx, Novartis

Novartis has won FDA approval for Cosentyx (secukinumab) for the treatment of two new indications – adults with active ankylosing …

News
AS spine fusion

Novartis’ Cosentyx shows benefits in Phase III AS trials

January 4, 2016
Research and Development, Sales and Marketing Cosentyx, Novartis, Secukinumab, ankylosing spondylitis

Novartis says results from two Phase III studies for Cosentyx in ankylosing spondylitis (AS) showing significant clinical improvements versus placebo.Results …

News
cosentyx_logo

Novartis’ Cosentyx gets European approval for two conditions

October 23, 2015
Medical Communications, Sales and Marketing Cosentyx, European Medicines Agency, Novartis, psoriatic arthritis

The scientific committee of the European Medicines Agency (EMA) has recommended the approval of Novartis’ Cosentyx (secukinumab) for treatment of ankylosing …

News
Psoriasis

Novartis psoriasis drug shows three-year efficacy

October 12, 2015
Cosentyx, EADV, Novartis, Secukinumab, psoriasis

Novartis has announced new trial data confirming the efficacy of Cosentyx in patients with moderate-to-severe plaque psoriasis. The results of …

News

Novartis spends $200m on pain firm Spinifex

June 29, 2015
Sales and Marketing Cosentyx, EMA401, Novartis, Secukinumab, spinifex

Novartis is spending $200 million to increase its presence in pain management through the purchase of US-Australian biotech Spinifex Pharmaceuticals.  …

News

Latest content

FDA approves Amgen’s Imdelltra for extensive-stage small cell lung cancer

May 17, 2024

AstraZeneca shares results from phase 3 trial of COVID-19 prevention drug

May 17, 2024

GSK pledges £45m to Fleming Initiative to fight AMR

May 16, 2024

NeuroSense partners with PhaseV on upcoming phase 3 ALS trial

May 16, 2024

AstraZeneca adds new heart failure target through collaboration with BenevolentAI

May 15, 2024